ATRA

Atara Biotherapeutics (ATRA)

About Atara Biotherapeutics (ATRA)

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Details

Daily high
$9.61
Daily low
$8.56
Price at open
$9.61
52 Week High
$19.14
52 Week Low
$3.92
Market cap
87.9M
Dividend yield
0.00%
Volume
136,344
Avg. volume
84,716
P/E ratio
-11.06

Atara Biotherapeutics News

Details

Daily high
$9.61
Daily low
$8.56
Price at open
$9.61
52 Week High
$19.14
52 Week Low
$3.92
Market cap
87.9M
Dividend yield
0.00%
Volume
136,344
Avg. volume
84,716
P/E ratio
-11.06